Role of Oxidative Stress in Protein Misfolding and/or Amyloid Formation

Protein Misfolding Diseases: Current and Emerging Principles and Therapies

Volumn , Issue , 2010, Pages 615-630

  Scheinost, Johanna C ^a   Witter, Daniel P ^a   Boldt, Grant E ^a   Wentworth, Paul ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Lipid aldehydes and protein misfolding or amyloidogenesis; Oxidative stress, in vivo or ex vivo accompanied by lipid peroxidation, and peroxidized lipids present in biological systems; Role of oxidative stress in protein misfolding and or amyloid formation

Indexed keywords

EID: 84886216279     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470572702.ch28     Document Type: Chapter

References (77)

1. Hammond, E.M., Kaufmann, M.R., Giaccia, A.J. (2007). Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol, 19, 680-684.
2. Fruhwirth, G.O., Loidl, A., Hermetter, A. (2007). Oxidized phospholipids: from molecular properties to disease. Biochim Biophys Acta, 1772, 718-736.
3. Cecarini, V., Gee, J., Fioretti, E., Amici, M., Angeletti, M., Eleuteri, A.M., Keller, J.N. (2007). Protein oxidation and cellular homeostasis: emphasis on metabolism. Biochim Biophys Acta, 1773, 93-104.
4. Lee, Y.J., Shacter, E. (1999). Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem, 274, 19792-19798.
5. Lelli, J.L., Jr., Becks, L.L., Dabrowska, M.I., Hinshaw, D.B. (1998). ATP converts necrosis to apoptosis in oxidant-injured endothelial cells. Free Radic Biol Med, 25, 694-702.
6. Genestra, M. (2007). Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal, 19, 1807-1819.
7. Ames, B.N., Shigenaga, M.K., Hagen, T.M. (1993). Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A, 90, 7915-7922.
8. Beckman, K.B., Ames, B.N. (1998). The free radical theory of aging matures. Physiol Rev, 78, 547-581.
9. Carney, J.M., Smith, C.D., Carney, A.M., Butterfield, D.A. (1994). Aging-and oxygen-induced modifications in brain biochemistry and behavior. Ann N Y Acad Sci, 738, 44-53.
10. Cortopassi, G., Liu, Y., Hutchin, T. (1996). Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Exp Gerontol, 31, 253-265.
11. Gilchrest, B.A., Bohr, V.A. (1997). Aging processes, DNA damage, and repair. FASEB J, 11, 322-330.
12. Muller, F.L., Lustgarten, M.S., Jang, Y., Richardson, A., Van Remmen, H. (2007). Trends in oxidative aging theories. Free Radic Biol Med, 43, 477-503.
13. Krinsky, N.I. (1974). Singlet excited oxygen as a mediator of the antibacterial action of leukocytes. Science, 186, 363-365.
14. Zhao, W., Diz, D.I., Robbins, M.E. (2007). Oxidative damage pathways in relation to normal tissue injury. Br J Radiol, 80 Spec No 1, S23-S31.
15. Esterbauer, H., Schaur, R.J., Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med, 11, 81-128.
16. Fessel, J.P., Porter, N.A., Moore, K.P., Sheller, J.R., Roberts, L.J., 2nd. (2002). Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A, 99, 16713-16718.
17. Petersen, D.R., Doorn, J.A. (2004). Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med, 37, 937-945.
18. Stadtman, E.R., Levine, R.L. (2000). Protein oxidation. Ann N Y Acad Sci, 899, 191-208.
19. Smith, C.D., Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Stadtman, E.R., Floyd, R.A., Markesbery, W.R. (1991). Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A, 88, 10540-10543.
20. Agarwal, S., Sohal, R.S. (1994). Aging and proteolysis of oxidized proteins. Arch Biochem Biophys, 309, 24-28.
21. Grune, T., Klotz, L.O., Gieche, J., Rudeck, M., Sies, H. (2001). Protein oxidation and proteolysis by the nonradical oxidants singlet oxygen or peroxynitrite. Free Radic Biol Med, 30, 1243-1253.
22. Droge, W., Schipper, H.M. (2007). Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell, 6, 361-370.
23. Aksenova, M.V., Aksenov, M.Y., Carney, J.M., Butterfield, D.A. (1998). Protein oxidation and enzyme activity decline in old brown Norway rats are reduced by dietary restriction. Mech Ageing Dev, 100, 157-168.
24. Floyd, R.A. (1990). Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J, 4, 2587-2597.
25. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S.P., Wu, J.F., Carney, J.M., et al. (1995). Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem, 65, 2146-2156.
26. Rakhit, R., Cunningham, P., Furtos-Matei, A., Dahan, S., Qi, X.F., Crow, J.P., Cashman, N.R., Kondejewski, L.H., Chakrabartty, A. (2002). Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem, 277, 47551-47556.
27. Ursini, F., Davies, K.J., Maiorino, M., Parasassi, T., Sevanian, A. (2002). Atherosclerosis: another protein misfolding disease? Trends Mol Med, 8, 370-374.
28. Benedetti, A., Comporti, M., Esterbauer, H. (1980). Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta, 620, 281-296.
29. Cheng, J.Z., Singhal, S.S., Sharma, A., Saini, M., Yang, Y., Awasthi, S., Zimniak, P., Awasthi, Y.C. (2001). Transfection of mGSTA4 in HL-60 cells protects against 4-hydroxynonenal-induced apoptosis by inhibiting JNK-mediated signaling. Arch Biochem Biophys, 392, 197-207.
30. He, N., Singhal, S.S., Awasthi, S., Zhao, T., Boor, P.J. (1999). Role of glutathione S-transferase 8-8 in allylamine resistance of vascular smooth muscle cells in vitro. Toxicol Appl Pharmacol, 158, 177-185.
31. Kinter, M., Roberts, R.J. (1996). Glutathione consumption and glutathione peroxidase inactivation in fibroblast cell lines by 4-hydroxy-2-nonenal. Free Radic Biol Med, 21, 457-462.
32. Renes, J., de Vries, E.E., Hooiveld, G.J., Krikken, I., Jansen, P.L., Muller, M. (2000). Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J, 350 (Pt 2), 555-561.
33. Spitz, D.R., Malcolm, R.R., Roberts, R.J. (1990). Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in H2O2-resistant cell lines. Do aldehydic byproducts of lipid peroxidation contribute to oxidative stress? Biochem J, 267, 453-459.
34. Sullivan, S.J., Oberley, T.D., Roberts, R.J., Spitz, D.R. (1992). A stable O2-resistant cell line: role of lipid peroxidation byproducts in O2-mediated injury. Am J Physiol, 262, L748-L756.
35. Bieschke, J., Zhang, Q., Bosco, D.A., Lerner, R.A., Powers, E.T., Wentworth, P., Jr., Kelly, J.W. (2006). Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res, 39, 611-619.
36. Chen, K., Maley, J., Yu, P.H. (2006). Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem, 99, 1413-1424.
37. Janue, A., Olive, M., Ferrer, I. (2007). Oxidative stress in desminopathies and myotilinopathies: a link between oxidative damage and abnormal protein aggregation. Brain Pathol, 17, 377-388.
38. Stewart, C.R., Wilson, L.M., Zhang, Q., Pham, C.L., Waddington, L.J., Staples, M.K., Stapleton, D., Kelly, J.W., Howlett, G.J. (2007). Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry, 46, 5552-5561.
39. Zhang, Q., Powers, E.T., Nieva, J., Huff, M.E., Dendle, M.A., Bieschke, J., Glabe, C.G., Eschenmoser, A., Wentworth, P., Jr., Lerner, R.A., Kelly, J.W. (2004). Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A, 101, 4752-4757.
40. Zarkovic, K. (2003). 4-Hydroxynonenal and neurodegenerative diseases. Mol Aspects Med, 24, 293-303.
41. Sayre, L.M., Zelasko, D.A., Harris, P.L., Perry, G., Salomon, R.G., Smith, M.A. (1997). 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem, 68, 2092-2097.
42. Ando, Y., Brannstrom, T., Uchida, K., Nyhlin, N., Nasman, B., Suhr, O., Yamashita, T., Olsson, T., El Salhy, M., Uchino, M., Ando, M. (1998). Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci, 156, 172-176.
43. Castellani, R.J., Perry, G., Siedlak, S.L., Nunomura, A., Shimohama, S., Zhang, J., Montine, T., Sayre, L.M., Smith, M.A. (2002). Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett, 319, 25-28.
44. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., Mizuno, Y. (1996). Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A, 93, 2696-2701.
45. Babior, B.M., Takeuchi, C., Ruedi, J., Gutierrez, A., Wentworth, P., Jr. (2003). Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci U S A, 100, 3031-3034.
46. Datta, D., Vaidehi, N., Xu, X., Goddard, W.A., 3rd. (2002). Mechanism for antibody catalysis of the oxidation of water by singlet dioxygen. Proc Natl Acad Sci U S A, 99, 2636-2641.
47. Wentworth, P., Jr., Jones, L.H., Wentworth, A.D., Zhu, X., Larsen, N.A., Wilson, I.A., Xu, X., Goddard, W.A., 3rd, Janda, K.D., Eschenmoser, A., Lerner, R.A. (2001). Antibody catalysis of the oxidation of water. Science, 293, 1806-1811.
48. Wentworth, P., Jr., McDunn, J.E., Wentworth, A.D., Takeuchi, C., Nieva, J., Jones, T., Bautista, C., Ruedi, J.M., Gutierrez, A., Janda, K.D., et al. (2002). Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science, 298, 2195-2199.
49. Eanes, E.D., Glenner, G.G. (1968). X-ray diffraction studies on amyloid filaments. J Histochem Cytochem, 16, 673-677.
50. Glenner, G.G., Wong, C.W., Quaranta, V., Eanes, E.D. (1984). The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol, 2, 357-369.
51. Liu, Q., Raina, A.K., Smith, M.A., Sayre, L.M., Perry, G. (2003). Hydroxynonenal, toxic carbonyls, and Alzheimer disease. Mol Aspects Med, 24, 305-313.
52. Picklo, M.J., Montine, T.J., Amarnath, V., Neely, M.D. (2002). Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol, 184, 187-197.
53. Shigematsu, S., Takahashi, N., Hara, M., Yoshimatsu, H., Saikawa, T. (2007). Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J, 71, 1697-1702.
54. Uchida, K. (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res, 42, 318-343.
55. Hardy, J.A., Higgins, G.A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
56. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 300, 486-489.
57. Doorn, J.A., Petersen, D.R. (2003). Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem Biol Interact, 143-144, 93-100.
58. Haass, C., Steiner, H. (2001). Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat Neurosci, 4, 859-860.
59. Klein, W.L., Stine, W.B., Jr., Teplow, D.B. (2004). Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging, 25, 569-580.
60. Hardy, J. (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci, 20, 154-159.
61. Teplow, D.B., Lomakin, A., Kirschner, D.A., Walsh, D.M. (1997). Effects of betaprotein mutations on amyloid fibril nucleation and elongation. In Alzheimer's Disease: Biology, Diagnosis, and Therapeutics (Iqbak, K., (Ed.), Wiley, Chichester, UK, pp. 311-319.
62. Tsubuki, S., Takaki, Y., Saido, T.C. (2003). Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet, 361, 1957-1958.
63. Chiti, F., Dobson, C.M. (2006). Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem, 75, 333-366.
64. Casserly, I., Topol, E. (2004). Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, 363, 1139-1146.
65. Hartmann, T. (2001). Cholesterol, A beta and Alzheimer's disease. Trends Neurosci, 24, S45-S48.
66. Patrico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., Lee, V.M.-Y. (2001). Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci, 21, 4183-4187.
67. Sayre, L.M., Smith, M.A., Perry, G. (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem, 8, 721-738.
68. Markesbery, W.R., Carney, J.M. (1999). Oxidative alterations in Alzheimer's disease. Brain Pathol, 9, 133-146.
69. Mark, R.J., Lovell, M.A., Markesbery, W.R., Uchida, K., Mattson, M.P. (1997). A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem, 68, 255-264.
70. Siegel, S.J., Bieschke, J., Powers, E.T., Kelly, J.W. (2007). The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry, 46, 1503-1510.
71. Liu, L., Komatsu, H., Murray, I.V., Axelsen, P.H. (2008). Promotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product. J Mol Biol, 377, 1236-1250.
72. Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M., Ramponi, G., Dobson, C.M. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A, 96, 3590-3594.
73. Harper, J.D., Lansbury, P.T., Jr. (1997). Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the timedependent solubility of amyloid proteins. Annu Rev Biochem, 66, 385-407.
74. Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., Wentworth, P., Jr., Lerner, R.A., Kelly, J.W. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol, 2, 249-253.
75. Bieschke, J., Zhang, Q., Powers, E.T., Lerner, R.A., Kelly, J.W. (2005). Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry, 44, 4977-4983.
76. Scheinost, J.C., Wang, H., Boldt, G.E., Offer, J., Wentworth, P., Jr. (2008). Cholesterol seco-sterol-induced aggregation of methylated amyloid-beta peptides: insights into aldehyde-initiated fibrillization of amyloid-beta. Angew Chem Int Ed Engl, 47, 3919-3922.
77. Nelson, T.J., Alkon, D.L. (2005). Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem, 280, 7377-7387.